CoChat

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

Open access
Vacchelli, Erika, Aranda, Fernando, Eggermont, Alexander, Galon, Jérôme, Sautès-Fridman, Catherine, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo · 2014 · OncoImmunology
Cited by 81

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

, we provided a brief scientific background to the use of mAbs, all types confounded, in cancer therapy, and discussed the results of recent clinical trials investigating the safety and efficacy of this approach. Here, we focus on mAbs that primarily target malignant cells or their interactions with stromal components, as opposed to mAbs that mediate antineoplastic effects by activating the immune system. In particular, we discuss relevant clinical findings that have been published during the last 13 months as well as clinical trials that have been launched in the same period to investigate the therapeutic profile of hitherto investigational tumor-targeting mAbs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/onci.27048

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 81

Metadata

Authors
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L.
Venue
OncoImmunology
Published
2014-01
Volume
3
Issue
1
Pages
e27048
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2040706921
Cited by
81
References
16
FWCI
12.75
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. https://app.cochat.ai/papers/10.4161/onci.27048
The paper
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. OncoImmunology. https://doi.org/10.4161/onci.27048

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.